Citadel Advisors’s Aratana Therapeutics, Inc. PETX Stock Holding History

Citadel Advisors’s Portfolio PETX Stock Details PETX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-10,400	Closed	-$54K	–	10184
2019 Q2	$54K	Sell	10,400 -11,200	-52%	-$50.3K	﹤0.01%	8711
2019 Q1	$78K	Buy	+21,600	New	+$93.6K	﹤0.01%	8651
2018 Q3	–	Sell	-22,000	Closed	-$94K	–	9994
2018 Q2	$94K	Buy	+22,000	New	+$111K	﹤0.01%	8267
2017 Q3	–	Sell	-17,200	Closed	-$124K	–	8351
2017 Q2	$124K	Buy	17,200 +4,600	+37%	+$28.3K	﹤0.01%	6833
2017 Q1	$67K	Buy	+12,600	New	+$85.1K	﹤0.01%	6977

Other funds holding PETX

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

ASN

Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return

Citadel Advisors's PETX Position: Q3 2019 in Review

Citadel Advisors sold out of Aratana Therapeutics, Inc. (PETX) in Q3 2019, closing a stake of 30,557 shares — an estimated $158K sold.

Citadel Advisors first reported a position in PETX in Q3 2014 and held it in 16 quarters. The position peaked at $809K in Q4 2015. 2 funds tracked by Wall St. Rank hold PETX as of Q3 2019.

Citadel Advisors reported no remaining Aratana Therapeutics, Inc. position as of Q3 2019 after selling out during the quarter.
Citadel Advisors sold 30,557 Aratana Therapeutics, Inc. shares in Q3 2019, an estimated $158K.
Citadel Advisors first reported a position in Aratana Therapeutics, Inc. in Q3 2014 and held it in 16 quarters.
Citadel Advisors's Aratana Therapeutics, Inc. position peaked at $809K in Q4 2015.
2 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q3 2019.

Based on Citadel Advisors's 13F filing for Q3 2019, filed 14 Nov 2019.